{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Synthesize Responses from the Retrieved Contexts"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 0: Environment Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The .env file has been loaded\n"
     ]
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "from langchain_neo4j import Neo4jGraph\n",
    "from libs import create_vector_index, get_entities,embed_entity, vector_search,enhanced_chunk_finder\n",
    "import pandas as pd\n",
    "from conn import connect2Googlesheet\n",
    "from openai import OpenAI\n",
    "from synthlibs import graph_retriever, parse_relationships, final_context_builder,synthesize_response\n",
    "\n",
    "# plot figures in high resolution\n",
    "%config InlineBackend.figure_format = 'retina'\n",
    "# Force reload of the .env file\n",
    "try:\n",
    "    load_dotenv()\n",
    "    print(\"The .env file has been loaded\")\n",
    "except Exception as e:\n",
    "    print(\"The .env file has not been loaded. Reported error: \", e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Connected to Neo4j database successfully.\n",
      "The 'entities' index already exists.\n"
     ]
    }
   ],
   "source": [
    "# Connect to Neo4j database\n",
    "try:\n",
    "    graph = Neo4jGraph(\n",
    "        url=os.getenv(\"NEO4J_URL\"),\n",
    "        username=os.getenv(\"NEO4J_USERNAME\"),\n",
    "        password=os.getenv(\"NEO4J_PASSWORD\")\n",
    "    )\n",
    "    print(\"Connected to Neo4j database successfully.\")\n",
    "except ValueError as e:\n",
    "    print(f\"Could not connect to Neo4j database: {e}\")\n",
    "    \n",
    "# Check if the entities index exists\n",
    "index_name = \"entities\"\n",
    "query = \"SHOW INDEXES YIELD name, type WHERE type = 'VECTOR' AND name = $index_name\"\n",
    "\n",
    "result = graph.query(query, params={\"index_name\": index_name})\n",
    "if result:\n",
    "    print(\"The 'entities' index already exists.\")\n",
    "else:\n",
    "    create_vector_index(graph, \"entities\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 1: Connect to Google Sheet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>condition</th>\n",
       "      <th>number</th>\n",
       "      <th>docs</th>\n",
       "      <th>Question</th>\n",
       "      <th>Mahmud's Note</th>\n",
       "      <th>status</th>\n",
       "      <th>comments</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>1</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Does early administration of neuromuscular blo...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>2</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Do patients with severe ARDS being treated wit...</td>\n",
       "      <td>Replace</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>3</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>In patients with moderate to severe ARDS, does...</td>\n",
       "      <td>Maybe this question: In patients with moderate...</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>4</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have ...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Wrong concept since PEEP by itself is mandator...</td>\n",
       "      <td>Does the use of neuromuscular blockers in pati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>5</td>\n",
       "      <td>FACTT</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservat...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Check if studies defined conservative by CVP &lt;...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  condition  number      docs  \\\n",
       "0      ARDS       1  ACURASYS   \n",
       "1      ARDS       2  ACURASYS   \n",
       "2      ARDS       3      ROSE   \n",
       "3      ARDS       4      ROSE   \n",
       "4      ARDS       5     FACTT   \n",
       "\n",
       "                                            Question  \\\n",
       "0  Does early administration of neuromuscular blo...   \n",
       "1  Do patients with severe ARDS being treated wit...   \n",
       "2  In patients with moderate to severe ARDS, does...   \n",
       "3  Do patients with moderate-to-severe ARDS have ...   \n",
       "4  Among patients with ALI/ARDS, does a conservat...   \n",
       "\n",
       "                                       Mahmud's Note status  \\\n",
       "0                                               Like          \n",
       "1                                            Replace  fixed   \n",
       "2  Maybe this question: In patients with moderate...  fixed   \n",
       "3  Local question (not sure if this is the aim of...  fixed   \n",
       "4  Local question (not sure if this is the aim of...  fixed   \n",
       "\n",
       "                                            comments  \\\n",
       "0                                                      \n",
       "1                                                      \n",
       "2                                                      \n",
       "3  Wrong concept since PEEP by itself is mandator...   \n",
       "4  Check if studies defined conservative by CVP <...   \n",
       "\n",
       "                                                      \n",
       "0                                                     \n",
       "1                                                     \n",
       "2                                                     \n",
       "3  Does the use of neuromuscular blockers in pati...  \n",
       "4                                                     "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Doc No</th>\n",
       "      <th>Confirmed by</th>\n",
       "      <th>Topic</th>\n",
       "      <th>Name</th>\n",
       "      <th>Study Design and Methodology</th>\n",
       "      <th>Study Population</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Comparator</th>\n",
       "      <th>Outcomes</th>\n",
       "      <th>Strengths and Weaknesses</th>\n",
       "      <th>Key Findings and Conclusion</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td></td>\n",
       "      <td>ARDS</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>- Multicenter, randomized, double-blind, place...</td>\n",
       "      <td>The study enrolled 340 patients from 20 ICUs i...</td>\n",
       "      <td>- Cisatracurium Group:\\n  - 3-ml rapid IV infu...</td>\n",
       "      <td>- Placebo group receiving identical IV infusio...</td>\n",
       "      <td>Primary Outcome:\\n- 90-day in-hospital mortali...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- Blinded ra...</td>\n",
       "      <td>Key Findings:\\n- Adjusted 90-day survival impr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>6</td>\n",
       "      <td></td>\n",
       "      <td>ARDS</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>- Multicenter, unblinded, randomized clinical ...</td>\n",
       "      <td>- Patients with moderate-to-severe ARDS\\n- Cri...</td>\n",
       "      <td>- 48-hour continuous infusion of cisatracurium...</td>\n",
       "      <td>- Usual care approach\\n- No routine neuromuscu...</td>\n",
       "      <td>Primary Outcome:\\n- In-hospital death from any...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- High proto...</td>\n",
       "      <td>Key Findings:\\n No significant difference in 9...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td></td>\n",
       "      <td>ARDS</td>\n",
       "      <td>FACTT</td>\n",
       "      <td>- Prospective, randomized clinical trial\\n- Co...</td>\n",
       "      <td>- 1,001 patients with acute lung injury (503 i...</td>\n",
       "      <td>Conservative Strategy:\\n- Lower fluid intake\\n...</td>\n",
       "      <td>The two fluid management strategies were compa...</td>\n",
       "      <td>Primary Outcome:\\n- Death at 60 days\\n\\nSecond...</td>\n",
       "      <td>Strengths:\\n- Randomized design\\n- Multi-cente...</td>\n",
       "      <td>Key Findings:\\n- No significant difference in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td></td>\n",
       "      <td>ARDS</td>\n",
       "      <td>ARDSNet</td>\n",
       "      <td>- Multicenter, randomized controlled trial\\n- ...</td>\n",
       "      <td>- Total Participants: 861 patients\\n- Inclusio...</td>\n",
       "      <td>- Lower Tidal Volume Group:\\n  - Initial tidal...</td>\n",
       "      <td>- Traditional Tidal Volume Group:\\n  - Initial...</td>\n",
       "      <td>Primary Outcomes:\\n- Mortality before hospital...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- Robust ran...</td>\n",
       "      <td>Key Findings:\\n- Mortality reduced by 22% in l...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td></td>\n",
       "      <td>ARDS</td>\n",
       "      <td>PROSEVA</td>\n",
       "      <td>- Multicenter, prospective, randomized, contro...</td>\n",
       "      <td>- 466 patients with severe ARDS\\n- Inclusion c...</td>\n",
       "      <td>- Prone group (237 patients):\\n  - Turned to p...</td>\n",
       "      <td>- Supine group (229 patients):\\n  - Remained i...</td>\n",
       "      <td>Primary Outcome:\\n- 28-day mortality\\n\\nSecond...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- Standardiz...</td>\n",
       "      <td>Key Findings:\\n- 28-day mortality: 16.0% (pron...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Doc No Confirmed by Topic      Name  \\\n",
       "0      1               ARDS  ACURASYS   \n",
       "1      6               ARDS      ROSE   \n",
       "2      3               ARDS     FACTT   \n",
       "3      2               ARDS   ARDSNet   \n",
       "4      5               ARDS   PROSEVA   \n",
       "\n",
       "                        Study Design and Methodology  \\\n",
       "0  - Multicenter, randomized, double-blind, place...   \n",
       "1  - Multicenter, unblinded, randomized clinical ...   \n",
       "2  - Prospective, randomized clinical trial\\n- Co...   \n",
       "3  - Multicenter, randomized controlled trial\\n- ...   \n",
       "4  - Multicenter, prospective, randomized, contro...   \n",
       "\n",
       "                                    Study Population  \\\n",
       "0  The study enrolled 340 patients from 20 ICUs i...   \n",
       "1  - Patients with moderate-to-severe ARDS\\n- Cri...   \n",
       "2  - 1,001 patients with acute lung injury (503 i...   \n",
       "3  - Total Participants: 861 patients\\n- Inclusio...   \n",
       "4  - 466 patients with severe ARDS\\n- Inclusion c...   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0  - Cisatracurium Group:\\n  - 3-ml rapid IV infu...   \n",
       "1  - 48-hour continuous infusion of cisatracurium...   \n",
       "2  Conservative Strategy:\\n- Lower fluid intake\\n...   \n",
       "3  - Lower Tidal Volume Group:\\n  - Initial tidal...   \n",
       "4  - Prone group (237 patients):\\n  - Turned to p...   \n",
       "\n",
       "                                          Comparator  \\\n",
       "0  - Placebo group receiving identical IV infusio...   \n",
       "1  - Usual care approach\\n- No routine neuromuscu...   \n",
       "2  The two fluid management strategies were compa...   \n",
       "3  - Traditional Tidal Volume Group:\\n  - Initial...   \n",
       "4  - Supine group (229 patients):\\n  - Remained i...   \n",
       "\n",
       "                                            Outcomes  \\\n",
       "0  Primary Outcome:\\n- 90-day in-hospital mortali...   \n",
       "1  Primary Outcome:\\n- In-hospital death from any...   \n",
       "2  Primary Outcome:\\n- Death at 60 days\\n\\nSecond...   \n",
       "3  Primary Outcomes:\\n- Mortality before hospital...   \n",
       "4  Primary Outcome:\\n- 28-day mortality\\n\\nSecond...   \n",
       "\n",
       "                            Strengths and Weaknesses  \\\n",
       "0  Strengths:\\n- Multicenter design\\n- Blinded ra...   \n",
       "1  Strengths:\\n- Multicenter design\\n- High proto...   \n",
       "2  Strengths:\\n- Randomized design\\n- Multi-cente...   \n",
       "3  Strengths:\\n- Multicenter design\\n- Robust ran...   \n",
       "4  Strengths:\\n- Multicenter design\\n- Standardiz...   \n",
       "\n",
       "                         Key Findings and Conclusion  \n",
       "0  Key Findings:\\n- Adjusted 90-day survival impr...  \n",
       "1  Key Findings:\\n No significant difference in 9...  \n",
       "2  Key Findings:\\n- No significant difference in ...  \n",
       "3  Key Findings:\\n- Mortality reduced by 22% in l...  \n",
       "4  Key Findings:\\n- 28-day mortality: 16.0% (pron...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "spreadsheet = connect2Googlesheet()\n",
    "\n",
    "# Select the worksheet: relevance\n",
    "Q_worksheet = spreadsheet.get_worksheet(2)  \n",
    "# Select the worksheet: revised summary\n",
    "Sum_worksheet = spreadsheet.get_worksheet(6) \n",
    "\n",
    "# Get all records as a list of dictionaries\n",
    "ques_data = Q_worksheet.get_all_records()\n",
    "sum_data = Sum_worksheet.get_all_records()\n",
    "\n",
    "# Convert to Pandas DataFrame\n",
    "df_MedQ = pd.DataFrame(ques_data)\n",
    "df_MedSum = pd.DataFrame(sum_data)\n",
    "\n",
    "# Display the first few rows of both DataFrames\n",
    "display(df_MedQ.head())\n",
    "display(df_MedSum.head())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 2: Build Context before Synthesis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: Does early administration of neuromuscular blocking agents increases the ventilator free days?\n",
      "Found 26 unique relationships:\n",
      "- furosemide -> prescribed -> administration\n",
      "- administration -- prescribed -- Lite protocol\n",
      "- administration -- prescribed -- FACTT Lite\n",
      "- administration -- prescribed -- FACTT Conservative\n",
      "- administration -- prescribed -- FACTT Liberal\n",
      "- administration -- prescribed -- FACTT protocols\n",
      "- neuromuscular blocking agents -> prescribed -> severely hypoxemic patients\n",
      "- neuromuscular blocking agents -- prescribed -- prone positioning\n",
      "- neuromuscular blocking agents -> prescribed -> patients with early, severe ARDS\n",
      "- neuromuscular blocking agents -- registered -- intensive care unit (ICU)\n",
      "- neuromuscular blocking agents -- received -- therapy with neuromuscular blocking agents\n",
      "- neuromuscular blocking agents -> falls_under -> pharmacologic intervention\n",
      "- neuromuscular blocking agents -> resulted_in -> improve the prognosis of moderate-to-severe ARDS\n",
      "- neuromuscular blocking agents -> resulted_in -> decrease ventilator-induced lung injury\n",
      "- neuromuscular blocking agents -> resulted_in -> improve oxygenation\n",
      "- neuromuscular blocking agents -> resulted_in -> muscle weakness\n",
      "- Study drug -> resulted_in -> Ventilator-free days\n",
      "- Ventilator-free days -- is_concomitant -- Postprotocol sedative medications\n",
      "- Ventilator-free days -- prescribed -- 0.5 mg per kilogram of predicted body weight every 12 hours for 7 days\n",
      "- Ventilator-free days -- prescribed -- tapering of the dose over a period of 4 days\n",
      "- Ventilator-free days -- prescribed -- 0.5 mg per kilogram of predicted body weight every 6 hours for 14 days\n",
      "- Ventilator-free days -- resulted_in -- Delirium-free days\n",
      "- Ventilator-free days -- resulted_in -- Time on mechanical ventilation\n",
      "- Ventilator-free days -- resulted_in -- Daily prevalence of delirium\n",
      "- Ventilator-free days -- resulted_in -- Coma-free days\n",
      "- Ventilator-free days -- resulted_in -- Lengths of stay on the MV and in the ICU\n"
     ]
    }
   ],
   "source": [
    "test_question = df_MedQ['Question'][0]\n",
    "context = graph_retriever(graph, test_question, max_depth=2)\n",
    "formatted_relations = parse_relationships(context)\n",
    "print(formatted_relations)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: Does early administration of neuromuscular blocking agents increases the ventilator free days?\n",
      "Found 26 unique relationships:\n",
      "- furosemide -> prescribed -> administration\n",
      "- administration -- prescribed -- Lite protocol\n",
      "- administration -- prescribed -- FACTT Lite\n",
      "- administration -- prescribed -- FACTT Conservative\n",
      "- administration -- prescribed -- FACTT Liberal\n",
      "- administration -- prescribed -- FACTT protocols\n",
      "- neuromuscular blocking agents -> prescribed -> severely hypoxemic patients\n",
      "- neuromuscular blocking agents -- prescribed -- prone positioning\n",
      "- neuromuscular blocking agents -> prescribed -> patients with early, severe ARDS\n",
      "- neuromuscular blocking agents -- registered -- intensive care unit (ICU)\n",
      "- neuromuscular blocking agents -- received -- therapy with neuromuscular blocking agents\n",
      "- neuromuscular blocking agents -> falls_under -> pharmacologic intervention\n",
      "- neuromuscular blocking agents -> resulted_in -> improve the prognosis of moderate-to-severe ARDS\n",
      "- neuromuscular blocking agents -> resulted_in -> decrease ventilator-induced lung injury\n",
      "- neuromuscular blocking agents -> resulted_in -> improve oxygenation\n",
      "- neuromuscular blocking agents -> resulted_in -> muscle weakness\n",
      "- Study drug -> resulted_in -> Ventilator-free days\n",
      "- Ventilator-free days -- is_concomitant -- Postprotocol sedative medications\n",
      "- Ventilator-free days -- prescribed -- 0.5 mg per kilogram of predicted body weight every 12 hours for 7 days\n",
      "- Ventilator-free days -- prescribed -- tapering of the dose over a period of 4 days\n",
      "- Ventilator-free days -- prescribed -- 0.5 mg per kilogram of predicted body weight every 6 hours for 14 days\n",
      "- Ventilator-free days -- resulted_in -- Delirium-free days\n",
      "- Ventilator-free days -- resulted_in -- Time on mechanical ventilation\n",
      "- Ventilator-free days -- resulted_in -- Daily prevalence of delirium\n",
      "- Ventilator-free days -- resulted_in -- Coma-free days\n",
      "- Ventilator-free days -- resulted_in -- Lengths of stay on the MV and in the ICU\n",
      " And Given the following context in the format [(File Name, Text),...] \n",
      "[('LSPA.pdf', ' clinical trials have shown that early mobilization in both medical and surgical  critically ill patients is safe and associated with increased ventilator-free days and improved  physical function at hospital discharge.22–25 Early mobilization is limited by use of deep  sedation and development of delirium, which can be minimized through the use of scale- based targeted light sedation is implemented early on.26 After reviewing this literature in 2013, the Society of Critical Care Medicine (SCCM)’s'), ('ESCPARDS.pdf', '-day mortality rates among patients enrolled at least 14 days after the onset  of ARDS. Methylprednisolone increased the number of ventilator-free and shock- free days during the first 28 days in association with an improvement in oxygen- ation, respiratory-system compliance, and blood pressure with fewer days of vaso- pressor therapy. As compared with placebo, methylprednisolone did not increase  the rate of infectious complications but was associated with a higher rate'), ('DDS.pdf', ' mediated by a blunted immune response, resulting in an improved microcirculation [7], or enhanced adrener- gic receptor sensitivity [8]. Dexmedetomidine is a highly selective alpha-2 adre- noreceptor agonist that has sedative, anxiolytic, and opioid-sparing effects (Table 2) [9, 10]. The use of dexmedetomidine in critically ill patients increased ventilator-free time [11] and decreased'), ('DDS.pdf', 'medetomidine in critically ill patients increased ventilator-free time [11] and decreased the incidence of postoperative complications, delirium, and mortality up to 1 year post-cardiac surgery [12]. In postoperative patients, dexmedetomidine provided sympatholytic ac- tivity [13]. It also offers anti-inflammatory and organ protective effects in animal models [14]. The use of dexmedetomidine as an anti-adrenergic strategy in se'), ('ETSDMV.pdf', '▪ Randomized placebo-controlled clinical trial of low dose nighttime  dexmedetomidine to prevent ICU delirium. Notable for being one of the few interventions shown  to prevent ICU delirium. 30. Kawazoe Y, Miyamoto K, Morimoto T, et al. Effect of dexmedetomidine on mortality and  ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical  trial effect of dexmed'), ('FMWSCPARDS.pdf', ' significantly lower  cumulative fluid balance by 5,074 mL over 7 days than FACTT Liberal. In subjects without  baseline shock, in whom the fluid protocol was applied throughout the duration of the study,  management with FACTT Lite resulted in an equivalent cumulative fluid balance to FACTT  Conservative. FACTT Lite had similar clinical outcomes of ventilator-free days, ICU-free  days, and mortality as FACTT Conservative and significantly greater ventilator-'), ('APROCCHSS.pdf', '-free days to day 28 was signifi- cantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group  (17 vs. 15 days, P<0.001), as was the number of organ-failure–free days (14 vs. 12 days,  P\\u2009=\\u20090.003). The number of ventilator-free days was similar in the two groups (11 days in  the'), ('FMWSCPARDS.pdf', ' be easily understood and implemented by  physician and nursing staff in the ICU. Conclusions Although the FACTT Lite protocol had a greater cumulative fluid balance than FACTT  Conservative, the results of our study indicate that the FACTT Lite protocol is safe and has  equivalent ventilator-free days, ICU-free days, acute kidney injury, and adjusted 60-day  mortality to FACTT Conservative. FACTT Conservative has improved ventilator-free days,'), ('FMWSCPARDS.pdf', ' mortality to FACTT Conservative. FACTT Conservative has improved ventilator-free days,  ICU-free days, and prevalence of acute kidney injury than FACTT Liberal. FACTT Lite can  be used as a simplified and safe alternative to FACTT Conservative for the management of  fluid balance in patients with ARDS. Supplementary Material Refer to Web version on PubMed Central for supplementary material. Acknowledgments Supported, in part, by the National Institutes of Health, National'), ('FMWSCPARDS.pdf', 'T Liberal (11%) (p = 0.18 vs Lite). Conclusions—FACTT Lite had a greater cumulative fluid balance than FACTT Conservative  but had equivalent clinical and safety outcomes. FACTT Lite is an alternative to FACTT  Conservative for fluid management in Acute Respiratory Distress Syndrome. Keywords acute kidney injury; adult respiratory distress syndrome; clinical protocols; critical illness; fluid  therapy; shock Conservative fluid management improves ventilator-free days and'), ('ARDSSRDRFMS.pdf', ' compared monitoring patients with ARDS with a pulmonary artery versus central venous catheter. Clinical data and biologic samples for this analysis were obtained on study enrollment, before randomization. There was no difference in 60-day mortality with either intervention (8, 9). Patients assigned to the ﬂuid-conservative group had signiﬁcantly more ventilator-free days (8). Latent Class Analysis To estimate the optimal number of classes that best ﬁt the'), ('ETSDMV.pdf', ' al. [31▪▪] recently published the  results of a large, multicenter, randomized controlled trial studying early dexmedetomidine  in mechanically ventilated patients. The study showed no difference in mortality at 90 or 180  days, or in ventilator free days. However, more than half the patients in both groups failed to  achieve the targeted light sedation goal and three quarters of patients in the  dexmedetomidine group also received propofol,'), ('APROCCHSS.pdf', ' number of ventilator-free days was similar in the two groups (11 days in  the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P\\u2009=\\u20090.07). The  rate of serious adverse events did not differ significantly between the two groups, but  hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS In this trial'), ('ARDSSRDRFMS.pdf', '�uid-liberal versus a ﬂuid- conservative approach, although those subjects randomized to ﬂuid-conservative therapy had more ventilator-free days (8). As a result, a ﬂuid-conservative approach has been recommended for all patients with ARDS once shock has resolved (17). Our ﬁndings, however, suggest that there may be heterogeneity of treatment effects of ﬂuid-management strategy in ARDS (18). Subjects in subp'), ('ESCPARDS.pdf', '.1 cm of  water, respectively; P = 0.004) (Table 4 of the Sup- plementary Appendix). The methylprednisolone group had signifi- cantly more ventilator-free days than the placebo  group during the first 28 days (Table 2) as well  as at 180 days (Table 3). Patients given methyl- prednisolone were able to breathe without assis- tance sooner than patients given placebo (14.1 '), ('EDvsLSMENDS.pdf', 'Pandharipande et al. Critical Care 2010, 14:R38 http://ccforum.com/content/14/2/R38 Page 5 of 12 2.8) more delirium-free days, and 6 (0.3 to 11.0) more ventilator-free days than patients receiving LZ, after adjusting for relevant covariates. However, no substantial difference was seen in these outcomes between non-sep- tic patients treated with DEX'), ('RDSCI.pdf', ' Morimoto T, et\\xa0al. Effect of dex- medetomidine on mortality and ventilator-free days in patients  requiring mechanical ventilation with sepsis: a randomized  clinical trial. JAMA. 2017;317:1321-1328. doi:10.1001/ jama.2017.2088 \\t 8.\\t Shehabi Y, Bellomo R, Reade MC, et\\xa0al. Early intensive care  sedation predicts long-term mortality'), ('ESCNBC.pdf', ' undergoing at least 2\\xa0days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48\\xa0h  from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commence- ment of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day  in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in  the numbers of ventilator-free days ('), ('RARDS.pdf', ' Proportion of patients with rapidly resolving ARDS, ventilator-free days, and intensive care unit (ICU)–free days were the secondary outcomes of our analysis. ARDS was considered rapidly resolving if the patient had a PaO2/FIO2 over 300 mm Hg within 24 hours after enrollment or achieved unassisted breathing within 24 hours after enrollment and remained free from assisted breathing for 48 hours or more. Ventilator-free days and ICU-free days were the'), ('ESCPARDS.pdf', 'osteroids in patients with persistent ARDS. Methods We randomly assigned 180 patients with ARDS of at least seven days’ duration to  receive either methylprednisolone or placebo in a double-blind fashion. The primary  end point was mortality at 60 days. Secondary end points included the number of  ventilator-free days and organ-failure–free days, biochemical markers of inflamma- tion and fibroproliferation, and infectious complications. Results At 60')]\n"
     ]
    }
   ],
   "source": [
    "final_context , filenames = final_context_builder(graph, test_question, method=\"hybrid\")\n",
    "#res = get_firstk_chunks(graph, filenames, firstk=3)\n",
    "print(final_context)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 3: Synthesize"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.1 Stance Synthesis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_hy = synthesize_response(graph, test_question, synth_type = 'stance_synthesis', method=\"hybrid\", model=\"gpt-3.5-turbo\")\n",
    "response_vec= synthesize_response(graph, test_question, synth_type = 'stance_synthesis', method=\"vector\", model=\"gpt-3.5-turbo\")\n",
    "#response_gr= synthesize_response(graph, test_question, method=\"graph\", model=\"gpt-3.5-turbo\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hybrid Response:  {\n",
      "  \"DDS\": \"Supports\",\n",
      "  \"FMWSCPARDS\": \"Neutral\",\n",
      "  \"ESCNBC\": \"Neutral\",\n",
      "  \"APROCCHSS\": \"Neutral\",\n",
      "  \"LSPA\": \"Neutral\",\n",
      "  \"RARDS\": \"Neutral\",\n",
      "  \"ESCPARDS\": \"Neutral\",\n",
      "  \"EDvsLSMENDS\": \"Neutral\",\n",
      "  \"ETSDMV\": \"Neutral\",\n",
      "  \"RDSCI\": \"Neutral\"\n",
      "}\n",
      "Vector Response:  {\n",
      "  \"LSPA\": \"Neutral\",\n",
      "  \"ESCPARDS\": \"Against\",\n",
      "  \"DDS\": \"Supports\",\n",
      "  \"ETSDMV\": \"Neutral\",\n",
      "  \"FMWSCPARDS\": \"Neutral\",\n",
      "  \"APROCCHSS\": \"Neutral\",\n",
      "  \"ARDSSRDRFMS\": \"Neutral\",\n",
      "  \"EDvsLSMENDS\": \"Neutral\",\n",
      "  \"RDSCI\": \"Neutral\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "print(\"Hybrid Response: \", response_hy.choices[0].message.content.strip())\n",
    "print(\"Vector Response: \", response_vec.choices[0].message.content.strip())\n",
    "#print(\"Graph Response: \", response_gr.choices[0].message.content.strip())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.2 PICO Synthesis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_hy = synthesize_response(graph, test_question, synth_type = 'PICO_synthesis', method=\"hybrid\", model=\"gpt-3.5-turbo\")\n",
    "response_vec= synthesize_response(graph, test_question, synth_type = 'PICO_synthesis', method=\"vector\", model=\"gpt-3.5-turbo\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hybrid Response:  Based on the provided articles, here are the groupings and summaries:\n",
      "\n",
      "### Supporting the Claim:\n",
      "1. **Study 1: Dexmedetomidine and Ventilator-Free Time**\n",
      "   - **Authors**: Not specified\n",
      "   - **Year**: Not specified\n",
      "   - **Title**: Not specified\n",
      "   - **Journal**: Not specified\n",
      "   - **Research Question**: Effect of dexmedetomidine on ventilator-free time in critically ill patients.\n",
      "   - **Type of Study**: Study evaluating the impact of dexmedetomidine on ventilator-free time.\n",
      "   - **Methodology**: Dexmedetomidine increased ventilator-free time and decreased postoperative complications.\n",
      "   - **Population Size**: Not specified\n",
      "   - **Interventions**: Dexmedetomidine administration.\n",
      "   - **Outcomes**: Increased ventilator-free time and decreased complications.\n",
      "   - **Key Findings**: Dexmedetomidine increased ventilator-free time and reduced postoperative complications.\n",
      "\n",
      "### Equivocal or Inconclusive:\n",
      "1. **Study 2: Comparison of Sedation Agents in ICU Patients**\n",
      "   - **Authors**: Farina and Alaniz\n",
      "   - **Year**: 2019\n",
      "   - **Title**: Reconsidering Dexmedetomidine for Sedation in the Critically Ill\n",
      "   - **Journal**: Annals of Pharmacotherapy\n",
      "   - **Research Question**: Implications of the SPICE III Trial on dexmedetomidine use in ICU patients.\n",
      "   - **Type of Study**: Editorial discussing the findings of the SPICE III Trial on dexmedetomidine use.\n",
      "   - **Methodology**: SPICE III Trial compared dexmedetomidine to usual care for sedation in mechanically ventilated patients.\n",
      "   - **Key Findings**: SPICE III did not show significant differences in mortality, cognitive function, or quality of life between dexmedetomidine and usual care groups.\n",
      "\n",
      "### Refuting the Claim:\n",
      "No articles explicitly refuted the claim that early administration of neuromuscular blocking agents increases ventilator-free days.\n",
      "\n",
      "These summaries provide an overview of the relevant studies, their methodologies, outcomes, and key findings related to the impact of interventions like dexmedetomidine on ventilator-free days.\n",
      "Vector Response:  Based on the provided articles, we have the following groupings for articles related to the impact of early administration of interventions on ventilator-free days:\n",
      "\n",
      "### Supporting the Claim:\n",
      "1. **Article Title**: Dexmedetomidine in Critically Ill Patients\n",
      "   - **Authors**: Not specified\n",
      "   - **Year**: Not specified\n",
      "   - **Journal**: Not specified\n",
      "   - **Research Question**: Investigated the use of dexmedetomidine in critically ill patients.\n",
      "   - **Type of Study**: Not specified\n",
      "   - **Methodology**: Dexmedetomidine increased ventilator-free time and decreased postoperative complications and mortality.\n",
      "   - **Population Size**: Not specified\n",
      "   - **Interventions**: Dexmedetomidine administration.\n",
      "   - **Duration**: Not specified\n",
      "   - **Primary Outcome**: Increased ventilator-free time and decreased complications and mortality.\n",
      "\n",
      "2. **Article Title**: Conservative Fluid Management in ARDS\n",
      "   - **Authors**: Not specified\n",
      "   - **Year**: Not specified\n",
      "   - **Journal**: Not specified\n",
      "   - **Research Question**: Compared fluid management strategies in ARDS patients.\n",
      "   - **Type of Study**: Not specified\n",
      "   - **Methodology**: Conservative fluid management had equivalent ventilator-free days.\n",
      "   - **Population Size**: Not specified\n",
      "   - **Interventions**: Conservative fluid management protocol.\n",
      "   - **Duration**: 7 days\n",
      "   - **Primary Outcome**: Equivalent ventilator-free days compared to liberal fluid management.\n",
      "\n",
      "### Equivocal or Inconclusive:\n",
      "1. **Article Title**: Role of Neuromuscular Blocking Agents in COVID-19 ARDS\n",
      "   - **Authors**: Not specified\n",
      "   - **Year**: Not specified\n",
      "   - **Journal**: Not specified\n",
      "   - **Research Question**: Investigated the impact of early use of neuromuscular blocking agents on 90-day mortality in COVID-19 ARDS patients.\n",
      "   - **Type of Study**: Propensity score matching analysis.\n",
      "   - **Methodology**: No significant difference in 90-day mortality observed between groups.\n",
      "   - **Population Size**: 1953 patients included.\n",
      "   - **Interventions**: Neuromuscular blocking agents within 48 hours of IMV.\n",
      "   - **Primary Outcome**: No significant difference in 90-day mortality.\n",
      "\n",
      "### Refuting the Claim:\n",
      "No articles refuted the claim that early administration of interventions increases ventilator-free days based on the provided dataset.\n",
      "\n",
      "These summaries provide an overview of the key findings from the articles in each category.\n"
     ]
    }
   ],
   "source": [
    "print(\"Hybrid Response: \", response_hy.choices[0].message.content.strip())\n",
    "print(\"Vector Response: \", response_vec.choices[0].message.content.strip())"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
